EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction

Yuuri Kurokawa, Ayako Watanabe iD, Yuka Kashiwabara, Saori Fukuda, Shohei Nomoto, Ayako Kuriki, Kenji Momo iD

Clinical Case Reports · 2024-02 · 12 (2)

DOI: 10.1002/ccr3.8311 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 28.01.2024. Verfasst von Yuuri Kurokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Showa University Koto Toyosu Hospital Tokyo Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Clinical Message Most drugs that cause adverse events are difficult to identify in critically ill patients undergoing polypharmacy. We share our experience in identifying the causative drug among four suspect drugs administered during emergency treatment. Abstract We present the case of a 93‐year‐old man who was admitted for the treatment of cerebrovascular events. The patient was initially prescribed dual antiplatelet therapy with aspirin and clopidogrel along with lansoprazole, Hange‐koboku‐toh, and elobixibat. On day 36 after admission, the patient was found to have developed agranulocytosis. To improve his cerebrovascular prognosis, we first discontinued medications other than the anticoagulant medicines and initiated filgrastim. We discontinued clopidogrel 9 days after the discontinuation of the other medicines considering his low white blood cell count. One day after the discontinuation of clopidogrel, the agranulocytosis was alleviated. Considering the time course, clopidogrel, lansoprazole, Hange‐koboku‐toh, and elobixibat were suspected as the culprit medicines. This case highlights the considerable challenges encountered in clinical practice when attempting to identify the drugs responsible for agranulocytosis, particularly in patients on intensive medication therapy.

Schlagwörter

Stichwörter der Autor:innen

Hange‐Koboku‐Tohagranulocytosisclopidogrelelobixibatlansoprazolemultiple drug use

Autor:innen und Institutionen

  • Department of Pharmacy Showa University Koto Toyosu Hospital Tokyo Japan.
  • Department of Hospital Pharmaceutics, School of Pharmacy Showa University Tokyo Japan.
  • Department of Neurology Showa University Koto Toyosu Hospital Tokyo Japan.

ORCID-Profile: Ayako Watanabe, Kenji Momo

Zitieren

APA

Kurokawa, Y., Watanabe, A., Kashiwabara, Y., Fukuda, S., Nomoto, S., Kuriki, A., & Momo, K. (2024). Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction. Clinical Case Reports, 12(2). https://doi.org/10.1002/ccr3.8311

Vancouver

Kurokawa Y, Watanabe A, Kashiwabara Y, Fukuda S, Nomoto S, Kuriki A, et al. Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction. Clinical Case Reports. 2024;12(2). doi:10.1002/ccr3.8311

BibTeX
@article{Kurokawa2024,
  author = {Kurokawa, Yuuri and Watanabe, Ayako and Kashiwabara, Yuka and Fukuda, Saori and Nomoto, Shohei and Kuriki, Ayako and Momo, Kenji},
  title = {Identifying causative medications for agranulocytosis: A case report of an older adult with cerebral infarction},
  journal = {Clinical Case Reports},
  year = {2024},
  volume = {12},
  number = {2},
  doi = {10.1002/ccr3.8311}
}
Kostenlos starten →